The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biochemotherapy with interleukin-2 for metastatic melanoma: Long-term results in 100 patients.
David R. Minor
Consultant or Advisory Role - GlaxoSmithKline
Stock Ownership - Bristol-Myers Squibb (I)
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline
Mohammed Kashani-Sabet
No relevant relationships to disclose